GLP-1 medications are very concentrated, and only small amounts are needed per dose
However, while ER responses were not affected by SPHKAP knockdown, we detected a delay in the mitochondrial Ca 2+ response peak time in SPHKAP RNAi versus Control RNAi-treated WT INS-1 832/3 cells (Supplementary Fig
However, taking too much can increase liver damage risk
10.1186/s12916-024-03274-6 Summary Keywords GLP-1 receptor agonists, FAERS, adverse events, metabolism and nutrition disorders, pharmacovigilance Citation He L, Li Q, Yang Y, Li J, Luo W, Huang Y and Zhong X (2024) Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
Therefore, NCL urges consumers to learn about the safety risks associated with non-standard forms of GLP-1s and to heed these warnings from the FDA and medical authorities: Microdosing a GLP-1 drug means intentionally taking a smaller dose than what the FDA approved as the standard dosage levels for the treatment of obesity or diabetes based on clinical studies
